CBD Life Sciences Past Earnings Performance
Past criteria checks 0/6
CBD Life Sciences has been growing earnings at an average annual rate of 16.5%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been declining at an average rate of 20.6% per year.
Key information
16.5%
Earnings growth rate
82.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | -20.6% |
| Return on equity | -31.4% |
| Net Margin | -60.2% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How CBD Life Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 0 | 0 | 0 | 0 |
| 31 Dec 23 | 0 | 0 | 0 | 0 |
| 31 Mar 23 | 0 | -1 | 1 | 0 |
| 31 Dec 22 | 0 | -1 | 1 | 0 |
| 30 Jun 22 | 0 | -3 | 3 | 0 |
| 31 Mar 22 | 0 | -5 | 5 | 0 |
| 31 Dec 21 | 0 | -6 | 6 | 0 |
| 30 Sep 21 | 0 | -5 | 5 | 0 |
| 31 Dec 20 | 0 | -2 | 1 | 0 |
| 30 Sep 20 | 0 | -2 | 0 | 0 |
| 31 Dec 19 | 0 | -1 | 0 | 0 |
| 30 Sep 19 | 0 | -3 | 1 | 0 |
| 30 Jun 19 | 0 | -3 | 1 | 0 |
| 31 Mar 19 | 1 | -3 | 1 | 0 |
| 31 Dec 18 | 1 | -3 | 1 | 0 |
| 31 Dec 17 | 3 | 1 | 1 | 0 |
Quality Earnings: CBDL is currently unprofitable.
Growing Profit Margin: CBDL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CBDL is unprofitable, but has reduced losses over the past 5 years at a rate of 16.5% per year.
Accelerating Growth: Unable to compare CBDL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CBDL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).
Return on Equity
High ROE: CBDL has a negative Return on Equity (-31.4%), as it is currently unprofitable.